Swiss pharmaceutical giant Novartis has announced a massive $23 billion investment in US-based production, sparking hopes that President Donald Trump’s tariffs are working. The move is seen as a significant response to the president’s efforts to encourage companies to shift manufacturing from overseas to the US. Novartis, which produces top-selling drugs such as Entresto and Cosentyx for psoriasis, will expand its US operations to increase production capacity. The investment underscores the growing influence of US trade policy on global pharmaceutical companies.
Source: https://www.barrons.com/articles/novartis-stock-price-pharma-tariffs-6e30cb9e